A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia
Status:
Withdrawn
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This Phase 2 study was designed to evaluate the efficacy and safety of SNC-102 in subjects
with drug-induced Tardive Dyskinesia (TD). To ensure an adequate evaluation of SNC-102, a
randomized, double-blind, parallel-group, placebo-controlled trial was designed. Two dosing
levels of SNC-102 are employed to evaluate the proposed dosing range. A target enrollment of
90 subjects with drug-induced TD will provide sufficient data to assess the efficacy and
safety profiles of SNC-102 in the target population.